Drug Index


Mechanism :

It is a protease inhibitor (antiviral drug) used in the treatment of HIV infection.

Indication :

  • For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.

Contraindications :

Hypersensitivity (e.g., anaphylactic reaction, Stevens-Johnson syndrome)

QT and PR interval prolongation and torsades de pointes have been reported rarely; do not use saquinavir/ritonavir with congenital or documented acquired QT prolongation (>450 msec), refractory hypokalemia or magnesemia, and in combination with drugs that prolong QT interval.

Complete atrioventricular (AV) block without implanted pacemakers or high risk of complete AV block.

Severe hepatic impairment.

Coadministration of saquinavir/ritonavir with rifampin due to the risk of severe hepatotoxicity.

Drugs that are contraindicated with saquinavir (when coadministered ‘boosted’ with ritonavir) include CYP3A inhibitors that may result in increased saquinavir plasma levels and cause serious or life-threatening reactions (e.g., prolonged QT interval).

Drug contraindicated with saquinavir/ritonavir include alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine), trazodone, rifampin, voriconazole, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St. John’s wort, HMG-CoA reductase inhibitors (lovastatin, simvastatin), pimozide, sildenafil (when used for PAH), midazolam, and triazolam.

Dosing :

HIV Infection:
<16 years:
Safety and efficacy not established.
>16 years:
1000 mg (plus ritonavir 100 mg) PO every 12 hours.
In treatment-experienced children:
<2 years:
Not recommended.
≥2 years:
5 to <15 kg: 50 mg/kg (plus ritonavir 3 mg/kg) PO every 12 hours.
15-40 kg: 50 mg/kg (plus ritonavir 2.5 mg/kg) PO every 12 hours.
≥40 kg: 50 mg/kg (plus ritonavir 100 mg) PO every 12 hours.

Adverse Effect :

Rash, hyperglycemia, diarrhea, abdominal discomfort, nausea, abdominal pain, buccal mucosa ulceration, paresthesia, weakness.

Interaction :

Albuterol: Increase the toxicity by pharmacodynamic.
Alfuzosin: Increases the levels of alfuzosin by hepatic/intestinal metabolism.
Rifampin: Decreases the levels of saquinavir.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDUnlikely to be dialysed. Dose as in normal renal function
HDF/High fluxNot dialysed. Dose as in normal renal function
CAV/VVHDUnknown dialysability. Dose as in normal renal function

Hepatic Dose :

Mild to moderate hepatic impairment: No dosage adjustments are recommended but if a patient has an underlying liver disease like hepatitis B or C, cirrhosis there may be worsening. Therefore monitor liver function closely.
In severe hepatic impairment: Use is contraindicated.
01/24/2024 18:13:21 Saquinavir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0